¹ From Continuing Operations and does not consider Other Revenues/Expenses.
Strong portfolio of non-replicable leading brands in Brazil, including 18 power brands1
Key Facts
The Biggest
330+
People dedicated
300+
Manufacturing
to innovation
complex in
78%
250+
Latin America
brands
of board members
with relevant GICS
Launchings
level 1 industry
since 2018
experience
13.5%
R$770M+
350
of energy
Invested in
efficiency gains
R&D since 2018
(2020 vs. 2019)
Biggest team
Projects in
visiting POSs
50%
the pipeline
in Brazil
#1 in OTC,
with approx.
of women
20%
in the workforce
(36% in the
market share
leadership)
1 Brands with more than R$100 million in sell-out.
COD8432
Attachments
Original document
Permalink
Disclaimer
Hypera SA published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2021 13:56:01 UTC.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
